Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Beyond Abstinence: How Integrated Multidisciplinary Management Improves Long-term Post Liver Transplant Outcomes

AI Summary
  • Integrated multidisciplinary pre- and post-transplant programme, without mandated abstinence period, achieved low long-term relapse: 12.7% relapsed, 3.6% ongoing alcohol use.
  • Ethyl glucuronide testing confirmed relapse in 20 of 21 cases; median time to relapse 9.4 months; most patients regained abstinence after intensified support.
  • No alcohol-related deaths or graft losses observed; embedded addiction psychiatry and individualised relapse prevention were essential to favourable long-term outcomes.
Summarise with AI (MRCPsych/FRANZCP)

Transplantation. 2026 Oct 28. doi: 10.1097/TP.0000000000005939. Online ahead of print.

ABSTRACT

BACKGROUND: Alcohol-associated liver disease is the leading indication for liver transplantation (LT). We assessed long-term alcohol relapse after LT within a program using an integrated multidisciplinary team for relapse monitoring and prevention before and after transplantation, without requiring a predefined abstinence period.

METHODS: In 2018, we established a prospective program in which all patients with associated liver disease were evaluated and followed before and after LT by a multidisciplinary team embedded within the transplant program. We reviewed long-term outcomes as part of this program between 2018 and 2023.

RESULTS: A total of 165 recipients were transplanted since the inception of the program. Posttransplant alcohol relapse occurred in 21 patients (12.7%), of whom 57.1% had mild alcohol consumption, 4.8% moderate, and 33.3% severe. Median time to relapse was 9.4 mo (5.9-30.2). Ethyl glucuronide positivity confirmed relapse in 20 of 21 patients, and 17 endorsed alcohol use. All patients had access to addiction psychiatry follow-up and relapse prevention therapy embedded within their posttransplant care. Those who relapsed were offered intensification of relapse prevention therapy and 16/21 engaged in regular follow-up. Only 6 patients (3.6%) reported ongoing alcohol consumption at last follow-up, while all others reestablished abstinence. No significant differences in outcomes were observed between groups. No alcohol-related deaths or graft losses occurred.

CONCLUSIONS: A multidisciplinary fully integrated team along with individualized approach to candidate evaluation with follow-up pre- and post-LT is critical to successful outcomes and results in a much lower rate of relapse at long-term post-LT.

PMID:42950137 | DOI:10.1097/TP.0000000000005939

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

Save as PDF

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD